ICON Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
ICON wird ein jährliches Gewinn- und Umsatzwachstum von 13.7% bzw. 4.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.7% betragen.
Wichtige Informationen
13.7%
Wachstumsrate der Gewinne
14.4%
EPS-Wachstumsrate
Life Sciences Gewinnwachstum | 18.5% |
Wachstumsrate der Einnahmen | 4.9% |
Zukünftige Eigenkapitalrendite | 11.7% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 25 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
With A 25% Price Drop For ICON Public Limited Company (NASDAQ:ICLR) You'll Still Get What You Pay For
Nov 02Here's Why ICON (NASDAQ:ICLR) Has Caught The Eye Of Investors
Sep 25Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Sep 09We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt
Aug 25An Intrinsic Calculation For ICON Public Limited Company (NASDAQ:ICLR) Suggests It's 28% Undervalued
Aug 10ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)
Jul 13Earnings Tell The Story For ICON Public Limited Company (NASDAQ:ICLR)
Jun 14Here's Why We Think ICON (NASDAQ:ICLR) Is Well Worth Watching
May 30ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet
May 14ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 28What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump
Mar 05With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Feb 07ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?
Feb 01These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Jan 23Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jan 08What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E
Dec 24A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Dec 09With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Nov 08Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Oct 09Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Sep 23Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Sep 05Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?
Aug 03Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jun 30Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Jun 12Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
May 23Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Mar 29Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Mar 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?
Feb 21Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Dec 28These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Dec 10Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?
Nov 22Icon selected by BARDA to conduct anthrax vaccine clinical trial
Oct 06Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?
Sep 15ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly
Aug 26Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth
Aug 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?
Aug 01Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 9,128 | 1,059 | 1,348 | 1,511 | 13 |
12/31/2025 | 8,624 | 926 | 1,267 | 1,337 | 17 |
12/31/2024 | 8,312 | 735 | 1,096 | 1,232 | 17 |
9/30/2024 | 8,307 | 748 | 1,229 | 1,388 | N/A |
6/30/2024 | 8,332 | 714 | 1,182 | 1,327 | N/A |
3/31/2024 | 8,232 | 683 | 1,172 | 1,313 | N/A |
12/31/2023 | 8,120 | 612 | 1,020 | 1,161 | N/A |
9/30/2023 | 8,016 | 513 | 516 | 661 | N/A |
6/30/2023 | 7,903 | 510 | 381 | 534 | N/A |
3/31/2023 | 7,818 | 510 | 363 | 512 | N/A |
12/31/2022 | 7,741 | 505 | 421 | 563 | N/A |
9/30/2022 | 7,665 | 464 | 780 | 913 | N/A |
6/30/2022 | 7,588 | 210 | 878 | 998 | N/A |
3/31/2022 | 6,524 | 168 | 839 | 944 | N/A |
12/31/2021 | 5,481 | 153 | 735 | 829 | N/A |
9/30/2021 | 4,356 | 178 | 676 | 735 | N/A |
6/30/2021 | 3,191 | 364 | 506 | 548 | N/A |
3/31/2021 | 2,940 | 338 | 499 | 537 | N/A |
12/31/2020 | 2,797 | 328 | 527 | 568 | N/A |
9/30/2020 | 2,762 | 322 | 460 | 507 | N/A |
6/30/2020 | 2,771 | 324 | 502 | 556 | N/A |
3/31/2020 | 2,846 | 368 | 406 | 461 | N/A |
12/31/2019 | 2,806 | 369 | 374 | 413 | N/A |
9/30/2019 | 2,759 | 362 | 287 | 339 | N/A |
6/30/2019 | 2,704 | 353 | 257 | 306 | N/A |
3/31/2019 | 2,651 | 333 | 276 | 323 | N/A |
12/31/2018 | 2,596 | 323 | 220 | 269 | N/A |
9/30/2018 | 2,372 | 306 | 264 | 314 | N/A |
6/30/2018 | 2,157 | 295 | N/A | 294 | N/A |
3/31/2018 | 1,947 | 288 | N/A | 264 | N/A |
12/31/2017 | 1,758 | 281 | N/A | 383 | N/A |
9/30/2017 | 1,738 | 285 | N/A | 407 | N/A |
6/30/2017 | 1,718 | 274 | N/A | 350 | N/A |
3/31/2017 | 1,698 | 271 | N/A | 359 | N/A |
12/31/2016 | 1,666 | 262 | N/A | 259 | N/A |
9/30/2016 | 1,635 | 251 | N/A | 245 | N/A |
6/30/2016 | 1,609 | 249 | N/A | 267 | N/A |
3/31/2016 | 1,587 | 247 | N/A | 277 | N/A |
12/31/2015 | 1,575 | 240 | N/A | 279 | N/A |
9/30/2015 | 1,562 | 221 | N/A | 239 | N/A |
6/30/2015 | 1,555 | 210 | N/A | 275 | N/A |
3/31/2015 | 1,542 | 192 | N/A | 192 | N/A |
12/31/2014 | 1,503 | 172 | N/A | 169 | N/A |
9/30/2014 | 1,458 | 161 | N/A | 192 | N/A |
6/30/2014 | 1,411 | 138 | N/A | 125 | N/A |
3/31/2014 | 1,369 | 120 | N/A | 191 | N/A |
12/31/2013 | 1,336 | 103 | N/A | 221 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ICLRDas prognostizierte Gewinnwachstum (13.7% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: ICLRDie Erträge des Unternehmens (13.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.3% pro Jahr).
Hohe Wachstumserträge: ICLRDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ICLRDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: ICLRDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ICLRDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.7%).